Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Rottapharm Biotech s.r.l.
BioCentury | May 31, 2024
Product Development
Immunotherapies break into cold colorectal cancers at ASCO
Data from Regeneron, Agenus and others highlight immuno-oncology progress in genetically stable colorectal cancer
BioCentury | May 13, 2022
Finance
Italy solves its biotech chicken-and-egg problem
New funds and infrastructure to support company creation in Italy could in turn attract more investors and entrepreneurs
BioCentury | Dec 17, 2020
Finance
New Italian VC’s first play is Spanish biotech chasing notoriously difficult target
AurorA leads series A for Peptomyc
BioCentury | Aug 23, 2019
Targets & Mechanisms
New targets in osteoarthritis are about more than just pain
With mechanistic insights and a nudge from FDA, companies are taking OA past analgesics into disease-modifying targets
BioCentury | Oct 19, 2018
Emerging Company Profile
Altheia: Proliferating PD-L1
How Altheia is boosting PD-L1 expression to treat autoimmune diseases
Items per page:
1 - 10 of 13